Abstract Library

#2264 Metastatic Insulinoma: A Case-report of Complete Response to Peptide Receptor Radionuclide Therapy

Introduction: Insulinoma is a rare pancreatic neuroendocrine tumour. Metastatic insulinomas are a major therapeutic challenge.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Martins Branco D, Lucena Sampaio I, Brito M, Claro I,

Keywords: Insulinoma, PRRNT,

#781 Effect of Mean Absorbed Renal Dose on the Renal Function After Peptide Receptor Radionuclide Therapy

Introduction: Kidneys are the critical organs in peptide receptor radionuclide therapy (PRRNT) of neuroendocrine neoplasms (NENs).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Kulkarni H, Schuchardt C, Wiessalla S, Senftleben S, Baum R,

Keywords: mean absorbed renal dose, renal toxicity, peptide receptor radionuclide therapy,

#772 Role of Molecular Imaging using Ga-68 Somatostatin-Receptor PET/CT in Predicting Survival after Peptide Receptor Radionuclide Therapy of Neuroendocrine Neoplasms

Introduction: Peptide receptor radionuclide therapy (PRRNT) is valuable for the management of metastasized and/or inoperable neuroendocrine neoplasms (NENs).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Kaemmerer D

Authors: Kulkarni H, Kaemmerer D, Hommann M, Hörsch D, Baum R,

Keywords: somatostatin receptor PET/CT, peptide receptor radionuclide therapy, survival,

#571 Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Metastatic Neuroendocrine Tumors

Introduction: Liver transplantation is an important option for patients of neuroendocrine tumors (NET) with metastases limited to the liver. Peptide receptor radionuclide therapy (PRRNT) is effective in the management of metastatic NET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Hoersch D, Hommann M, Baum R,

Keywords: liver transplantation, peptide receptor radionuclide therapy,

#567 Efficacy of Combined Peptide Receptor Radionuclide Therapy and Radiofrequency Ablation for the Management of Hepatic Metastases of Neuroendocrine Tumors

Introduction: Hepatic metastases significantly affect the overall prognosis and quality of life in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET). Radiofrequency ablation (RFA) is one of the important local ablative strategies for hepatic metastases. Peptide receptor radionuclide therapy (PRRNT) is a well-established therapeutic modality for metastatic NET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Petrovich A, Hoersch D, Hommann M,

Keywords: Peptide receptor radionuclide therapy, radiofrequency ablation,